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ABSTRACT 
N-acetyltransferase 2 (NAT2) is the main enzyme metabolizing isoniazid and genotype-based treatment has been 
studied for years without becoming common practice. To investigate whether genotype-based isoniazid treatment 
is feasible in Greenland, we sequenced the coding sequence of NAT2 and determined the NAT2 enzyme-activity 
by caffeine test.  
No additional genetic variants were identified in the coding sequence of NAT2, so that genotype status in 260 study 
participants could be assessed by a well-established 7-SNP panel. Studying the enzyme activity by the ratio of the 
two caffeine metabolites AFMU and 1X in 260 participants showed a high rate of slow phenotypes with interme-
diate or rapid genotype. These misclassifications were mainly observed in urine samples with pH<3, a deviation 
from the standard protocol due to the field work character of the study, where immediate pH adjustment to pH=3.5 
was not possible. We excluded these samples. For the remaining 143 individuals with pH>3, we observed a mod-
erate level of discrepancies (19 of the 116 individuals with intermediate or rapid genotype status having a slow 
phenotype). Further investigation showed that drinking coffee and not tea or cola was the most important factor 
for high levels of both metabolites.  
The concordance between phenotype and genotype status with regard to slow metabolism supported the recom-
mendation of lower isoniazid doses in individuals with slow genotype status in order to avoid liver injury, a fre-
quent side effect. The phenotypical variation observed for individuals with intermediate or rapid genotype status 
warrants further research before increased dosing of isoniazid can be recommended. 
 
Keywords: N-acetyltransferase 2, Greenland, NAT2 genotype status, NAT2 enzyme activity, caffeine test, isoni-
azid 
Abbreviations: NAT2: N-acetyltransferase 2; TB: tuberculosis; SNP: single nucleotide polymorphism; 7-SNP 
panel: panel of seven SNPs in the coding sequence of NAT2 often used to determine the genotype status; IfADo: 
Leibniz Research Centre for Working Environment and Human Factors; AFMU: 5-acetylamino-6-formylamino-
3-methyluracil; 1X: 1-methylxanthine; IQR: inter quartile range; DQS: Dietary Quality Score; OR: odds ratio; 
95 %CI: 95 % confidence interval
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INTRODUCTION 
N-acetyltransferase 2 (NAT2) is a well-
studied acetylating enzyme involved in the 
metabolism of drugs used in the treatment of 
e.g. tuberculosis (TB), AIDS-associated dis-
eases and hypertension (McDonagh et al., 
2014; Weber, 1985). NAT2 acetylates the 
drugs in the liver prior to excretion at a genet-
ically determined rate. Variation in NAT2 ac-
tivity has also been linked to the risk of cancer 
due to its role in the metabolism of xenobiot-
ics (Figueroa et al., 2014; Hein, 2002; Marcus 
et al., 2000; Rothman et al., 2010; Tian et al., 
2014).  
The NAT2 gene is located on chromosome 
8p22 and has an 873 base pair coding se-
quence (Blum et al., 1990). The coding exon 
of NAT2 is polymorphic and frequencies of 
allelic variants vary between populations of 
different geographic and ethnic origins 
(Sabbagh et al., 2011). Currently, 45 variants 
in the coding sequence have been described. 
Most common variants are functionally rele-
vant and associated with reduced enzyme ac-
tivity, whereas the haplotype containing the 
reference alleles is associated with rapid en-
zyme activity. Thus, haplotypes derived from 
NAT2 genotypes are either associated with 
slow or rapid enzyme activity, resulting in 
three different outcomes for NAT2 genotype 
status: slow (two slow haplotypes), interme-
diate (one slow and one rapid haplotype) and 
rapid (two rapid haplotypes) (Hein and Doll, 
2012; Marchand et al., 1996). A panel of 
seven single nucleotide polymorphisms 
(SNPs) in the coding sequence is often used 
to determine the genotype status (7-SNP 
panel) (Hein and Doll, 2012) whereas analy-
sis of urinary metabolites after caffeine ad-
ministration (caffeine test) is considered the 
gold standard for measuring the enzyme ac-
tivity and assessing NAT2 phenotype status 
(Bolt et al., 2005; Grant et al., 1984). A high 
correlation between the detected phenotype 
status and the underlying genotype status has 
been demonstrated in several studies (Bolt et 
al., 2005; Butcher, 2002; Cascorbi et al., 
1995; Parkin et al., 1997; Tang et al., 1991; 
Zhao et al., 2000).  
Around 4000 years ago, the first humans 
came from the North American Arctic to 
Greenland and populated the island in several 
migration waves (Raghavan et al., 2014). 
Later immigration from Scandinavia over the 
last 300 years resulted in an additional Euro-
pean genetic component in the Greenlandic 
population. Recent studies have shown char-
acteristic variants in metabolic genes in 
Greenlandic Inuit; a TBC1D4 variant has been 
associated with type 2 diabetes and a CPT1A 
mutation associated with fatty acid metabo-
lism (Moltke et al., 2014; Skotte et al., 2017). 
It is therefore likely that Inuit hold other spe-
cific gene variants. We recently used the 7-
SNP panel to determine the NAT2 genotype 
status among 1,556 Greenlandic individuals 
(Geller et al., 2016). Our analyses showed a 
high frequency (36.4 %) of the rapid genotype 
status with a positive correlation between 
rapid genotype status and degree of Inuit an-
cestry. 
Greenland has a high incidence of TB and 
isoniazid is used for both treatment and pre-
vention of TB. A potential serious side effect 
of isoniazid treatment is liver injury (Azuma 
et al., 2012; Kinzig-Schippers et al., 2005; 
Wang et al., 2012), affecting mainly individ-
uals with slow phenotype status (Du et al., 
2013). Recent studies on the pharmacokinet-
ics of isoniazid suggested that individualizing 
treatment dose according to NAT2 genotype 
status could improve both the safety and effi-
cacy of treatment (Azuma et al., 2012; Jung et 
al., 2015). If a high proportion of the Inuit 
population presents with rapid enzyme activ-
ity, the response to TB treatment and preven-
tion might be lower than in other populations.  
The objective of the current study was to 
investigate whether a genotype-based treat-
ment with different doses of isoniazid can be 
recommended for Greenland. Therefore, we 
sequenced the coding region of NAT2 in 260 
participants to search for additional known or 
Inuit-specific sequence variants associated 
with NAT2 enzyme activity. Afterwards, we 
compared the NAT2 genotype status with phe-
notype status determined by the caffeine test.  
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MATERIAL AND METHODS 
Subjects 
Greenland is a self-governed part of Den-
mark. In 2013, we recruited individuals from 
seven towns in North, South, East and West 
Greenland for a genetic study and investi-
gated NAT2 genotypes for the 7-SNP panel in 
1,556 Greenlandic individuals (Geller et al., 
2016). For the current study, we re-invited all 
study participants from Sisimiut (n=374), 
Tasiilaq (n=167) and Nanortalik (n=168). 
Two weeks prior to enrolment, potential par-
ticipants received a letter of invitation and, if 
possible, were contacted by phone. Partici-
pants were asked to empty their bladders and 
consume a caffeinated beverage at home. 
Then participants came to the local hospital, 
gave written informed consent and were en-
rolled. A venous blood sample was drawn and 
later a urine sample was collected. While 
waiting, study participants completed a stand-
ardized self-administered questionnaire cov-
ering information on smoking, alcohol habits, 
diet, health and lifestyle (for details see Sup-
plementary Information). Basic variables in-
cluding medication, emptied bladder, bever-
age (coffee or tea/cola), number of cups 
drunk, time to urination, and food consumed 
during waiting time were asked from each 
participant. TB is a mandatory notifiable dis-
ease in Greenland and all cases are reported to 
the tuberculosis registry, maintained by the 
National Board of Health. Information on TB 
diagnosis was obtained through the tubercu-
losis registry. Treatment history for TB cases 
was evaluated through medical records. Addi-
tional information was obtained from ques-
tionnaires filled out by 88 % of the partici-
pants during the time between giving blood 
and urination. 
 
Sequencing and determination of NAT2 
haplotypes 
After blood sampling into a 9 ml EDTA 
tube, plasma and buffy coat were separated 
and stored at -20 C before transportation to 
Statens Serum Institut for DNA extraction. 
DNA was isolated from leukocytes in the 
buffy coat using Chemagic STAR DNA 
Buffy Coat kit BC200 (HAMILTON®). Dou-
ble strand sequencing of the coding region of 
exon 2 of NAT2 (873 bp) using Sanger tech-
nology took place at Eurofins MWG Operon, 
Ebersberg, Germany. 
Sequence data for all 260 participants 
were analyzed using NovoSNP3.0.1 (Weckx 
et al., 2005) and compared with the genotypes 
from the previous study (Geller et al., 2016). 
Two discrepancies (0.13 %) between the gen-
otype calls and the sequence calls were re-
solved by visual inspection of the sequence 
data and selecting the genotypes from se-
quencing. Haplotypes were estimated from 
the genotypes of the seven tagging SNPs with 
the algorithm implemented in the software 
PHASE (version 2.1.1) (Stephens and 
Donnelly, 2003). 
 
Caffeine test 
NAT2 enzyme activity was measured us-
ing a caffeine test suggested by Grant et al. 
(1984) and validated by the German Research 
Foundation (Blaszkewicz, 2002). After emp-
tying their bladder, the participants consumed 
1-3 cups of either coffee, tea or cola. Approx-
imately 1-3 hours after intake, a urine sample 
was collected from each participant. There 
was no need for fasting prior to urine collec-
tion. To adjust the urine simultaneously to an 
acidic pH in the pH range 3-5, samples were 
immediately filled into 10 mL sealable plastic 
tubes prepared with 38 mg dissolved sodium 
hydrogen sulfate monohydrate, a procedure 
experimentally established with 20 urine sam-
ples at the Leibniz Research Centre for Work-
ing Environment and Human Factors 
(IfADo). Due to the relative instability of one 
caffeine metabolite (Tang et al., 1983), sam-
ples were subsequently stored at -20 C and 
transported in ice-boxes to the IfADo for 
analysis. Here, pH measurements were per-
formed with a calibrated pH meter with a 
glass membrane. Creatinine in urine was 
measured with photometric microplate reader 
according to the Jaffe method (Blaszkewicz 
and Liesenhoff‐Henze, 2012). The secondary 
caffeine metabolites 5-acetylamino-6-formyl-
amino-3-methyluracil (AFMU) and 1-
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methylxanthine (1X) in urine were deter-
mined using high performance liquid chroma-
tography separation with UV detection. The 
AFMU/1X molar ratio was used as determi-
nant of phenotype status. All measurements 
were done in duplicates and the mean of the 
two ratios was used as an indicator of pheno-
type. A cut-off AFMU/1X of 0.85 distin-
guished between slow and intermediate/rapid 
phenotype status (Bolt et al., 2005; Braz 
Vieira da Silva Pontes et al., 1993).  
 
Statistical analyses 
Median and inter quartile range (IQR) of 
AFMU/1X were calculated for the basic vari-
ables ascertained at sample collection and the 
health and lifestyle components from the 
questionnaire. We analyzed the natural loga-
rithm of the metabolite measurements for 
AFMU, 1X and their ratio by multiple regres-
sion models in R. Factors were stepwise 
added to the model based on an inclusion p-
value of 0.05. Similarly, we analyzed the bi-
nary variable misclassification by logistic re-
gression in the subgroup with intermediate or 
rapid genotype status. 
 
RESULTS 
Of 709 potential participants, 265 (37  %) 
individuals accepted to participate, and of 
these 260 (70  % female) had the coding re-
gion of NAT2 sequenced and their AFMU and 
1X levels determined. Genotype status was 
assessed as rapid, intermediate or slow, de-
pending on the presence of 0, 1 or 2 slow hap-
lotypes, respectively. 
 
Sequencing and determination of NAT2 
haplotypes and genotype status 
Apart from the six SNPs of the 7-SNP-
panel that were polymorphic in Greenland in 
our previous study (Geller et al., 2016), no 
variation in the coding sequence of NAT2 was 
detected. The frequencies of the different 
NAT2 haplotypes are given in Table 1. The 
rapid haplotype *4 was most frequent in our 
study group (64 %), and the slow haplotypes 
were largely represented by *5B and *6A with 
19 % and 14 %, respectively. For additional 
analyses, we also investigated the subgroup of 
ultra-slow haplotypes (*6A or *7B) (Ruiz et 
al., 2012; Selinski et al., 2013), for which an 
increased risk of hepatotoxicity in TB patients 
has been reported (Higuchi et al., 2007). Ul-
tra-slow haplotypes were observed at a fre-
quency of 15 % in our study group. The gen-
otype distribution of the six SNPs is given in 
Supplementary Table 1.  
 
 
 
Table 1: Frequencies of NAT2 haplotypes in 260 study participants. Results based on the six SNPs 
from the 7-SNP panel that were polymorphic in the study group. 
rs name rs1041983 rs1801280 rs1799929 rs1799930 rs1208 rs1799931 Frequency 
Nucleotide- 
substitution 
 
C282T 
 
T341C 
 
C481T 
 
G590A 
 
A803G 
 
G857A 
 
Pheno-
type 
Haplo-
type 
       
Rapid *4 C T C G A G 64.4 % 
Slow *5B C C T G G G 18.9 % 
Ultra-
slow 
*6A T T C A A G 14.2 % 
Rapid *12A C T C G G G 1.0 % 
Ultra-
slow 
*7B T T C G A A 0.6 % 
Slow *5A C C T G A G 0.8 % 
Slow *5C C C C G G G 0.2 % 
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Quality control of caffeine test 
AFMU/1X measured by the caffeine test 
ranged from 0.004 to 6.34 (median 0.94, IQR: 
0.28-1.35) and 121 participants (47 %) were 
classified with slow phenotype status. Geno-
typically, only 16 % had a status associated 
with slow metabolism. To further investigate 
these misclassifications, we looked for factors 
influencing the metabolite levels and the ratio 
of them. It is known that an adjustment of 
urine to acidic pH is crucial for accurate 
measurements and it is recommended to ad-
just pH to 3.5 manually. However, in this field 
study samples were immediately filled into 10 
mL plastic tubes containing 38 mg dissolved 
sodium hydrogen sulfate monohydrate. Meas-
urements of pH in the laboratory varied from 
1.75 to 6.56. Statistical analysis revealed an 
association between pH values and log 
(AFMU/1X), r=0.32, p=1.0×10-7, which 
could explain AFMU/1X values resulting in 
misclassifications. To investigate whether 
this association was limited to a certain range 
of pH values, we split the samples in pH<3, 
pH between 3 and 4, and pH>4. Supplemen-
tary Table 2 shows the 2×3 tables for the three 
categories, with the 117 individuals in the 
group with pH<3 having 51 % misclassifica-
tion vs. 13 % in the remaining samples. We 
observed no increased rate of misclassifica-
tion in the group with pH>4. As we had no-
ticed discrepancies between phenotype and 
genotype status early on in the study, we had 
asked some participants to provide a second 
urine sample some days (median 6, range 2-
43 days) after the first sample and 15 partici-
pants showed up a second time (Supplemen-
tary Table 3) all other analyses are based on 
data related to participants’ first urine sample. 
Nine of ten misclassifications occur in urine 
samples with pH<3, including all four sam-
ples from two participants with slow 
AFMU/1X in both measurements despite in-
termediate/rapid genotype status. Given this 
evidence that urine samples with pH<3 do not 
provide reliable metabolite measurements for 
NAT2 phenotyping, we excluded all 117 par-
ticipants with pH<3 in their first samples from 
further analyses. The pH values in women 
(mean 3.19, 95 %CI: 3.05-3.33) were signifi-
cantly lower than in men (mean 3.68, 95 %CI: 
3.46-3.91), thus females accounted for 81 % 
of the excluded participants compared to 
70 % of the initial study group. In the remain-
ing 143 participants pH values and log 
(AFMU/1X) were no longer correlated, 
r=0.04, p=0.60. 
 
 
Table 2: Distribution of phenotype and genotype 
status for 143 study participants 
Group Genotype statusb 
 Slow Inter- 
mediate 
Rapid 
Phenotype  
statusa 
   
Slow 27 14 5 
Rapid 0 41 56 
aPhenotype status based on AFMU/1X with a cut-off of 0.85 
bGenotype status derived from the 7-SNP panel 
 
 
 
Distribution of AFMU/1X 
Figure 1 illustrates the distribution of the 
actual AFMU/1X over the three genotype sta-
tus groups in the remaining 143 participants, 
showing the wide range of ratios observed for 
intermediate and rapid genotype status. Sup-
plementary Table 2 presents AFMU/1X me-
dian and IQR for all basic and extended vari-
ables under investigation. The distribution of 
phenotype and genotype status is shown in 
Table 2. All 27 individuals with a slow geno-
type status had a slow phenotype status 
(100 % concordance), whilst 84 % (97 of 
116) of individuals with an intermediate or 
rapid genotype status presented with the ex-
pected intermediate/rapid phenotype. 
 
Analysis of metabolites AFMU, 1X and 
AFMU/1X 
To identify factors associated with the 19 
observed discrepancies between phenotype 
and genotype status, we built multiple regres-
sion models for the two metabolites 1X, 
AFMU, and AFMU/1X. The three outcomes 
had skewed distributions; so we applied a nat-
ural log-transformation to the values before 
analysis. 
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Table 3: Multiple linear regression model for (a) log(1X), N=111 due to missing values for some varia-
bles, (b) log(AFMU), N=111 due to missing values for some variables, (c) log(AFMU/1X), N=143. 
(a) Variable Estimate SE Pa Variance  explained 
Intercept 1.433 0.413   
Coffee 1.229 0.158 8.43×10-15 32.0% 
Intermediate genotype status -0.582 0.207 0.0017 5.3% 
Rapid genotype status -0.516 0.200 
Creatinine 0.472 0.105 1.22×10-6 10.4% 
Smoker 0.500 0.153 0.0038 3.4% 
Age 0.019 0.008 0.0169 2.3% 
Diet (DQS) 0.556 0.136 8.51×10-5 6.5% 
Sum    59.9% 
(b) Variable Estimate SE Pa Variance  explained 
Intercept -1.186 0.495   
Coffee 1.348 0.189 3.71×10-16 31.6% 
Intermediate genotype status 1.247 0.248 1.29×10-8 14.7% 
Rapid genotype status 1.703 0.239 
Creatinine 0.556 0.126 2.42×10-6 8.4% 
Smoker 0.532 0.183 0.0135 2.1% 
Age 0.035 0.009 2.65×10-4 4.8% 
Diet (DQS) 0.534 0.163 0.0014 3.6% 
Sum    65.3% 
(c) Variable Estimate SE Pa Variance  explained 
Intercept -2.126 0.207   
Intermediate genotype status 1.675 0.123 <2.2×10-16 70.7% 
Rapid genotype status 1.972 0.146 
Ultra-slow haplotypes -0.286 0.097 0.0027 1.7% 
Age 0.015 0.004 3.31×10-4 2.5% 
Sum    74.9% 
a – P and variance explained from analysis of variance (genotype status was analyzed as factor) 
 
 
 
Figure 1: Distribution of AFMU/1X according to 
genotype status for 143 study participants 
 
We investigated models with genotype 
status, laboratory measurements (pH, creati-
nine), basic information obtained at urine 
sample collection and information from ques-
tionnaires as explanatory variables. The final 
models from the stepwise regression for 1X, 
AFMU and AFMU/1X are given in Table 3. 
For AFMU and 1X the same six variables met 
the significance threshold of P≤0.05. The var-
iable indicating whether individuals drank 
coffee and not tea or cola was associated with 
a large increase in 1X and AFMU and ex-
plained about 32 % of the variance in both 
measurements. The difference in the effect es-
timates was small, and so coffee did not have 
a significant effect on AFMU/1X. The effect 
of genotype status was stronger for AFMU 
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(15 % variance explained) than for 1X (5 % 
variance explained). Creatinine levels had 
similar effects for both metabolites, explain-
ing up to 10 % of the variance. The remaining 
factors – smoking, age and diet – explained 
between 2 % and 7 % of the variation in the 
metabolite levels. Increased metabolite values 
were observed for smokers, older individuals 
and individuals with a higher (healthier) Die-
tary Quality Score (DQS) (Toft et al., 2006). 
Given our data, the effect of age was not a 
consequence of oral contraceptive use: ten 
women had answered that they were on oral 
contraceptives when asked for their medica-
tion and models including oral contraceptives 
had very similar effect estimates for age (all 
P≤0.05 for age), whereas the low powered 
analysis of oral contraceptive use did not re-
sult in any P≤0.05. For AFMU/1X, including 
the number of ultra-slow haplotypes *6A and 
*7B further improved the fit of the model. In 
total, the genotypes explain 72 % of the vari-
ance. The only other factor with a significant 
effect was age. Supplementary Table 5 pro-
vides a model for AFMU/1X also including 
the other four variables from the models for 
the individual metabolites, confirming that 
they have no significant effect on the ratio (all 
P>0.2).  
 
Analysis of misclassification 
The 13 % of misclassification observed is 
still somewhat higher than rates observed in 
similar studies. Therefore, we investigated 
misclassification as a binary outcome by lo-
gistic regression. All misclassifications oc-
curred in individuals presenting with slow 
phenotype status and intermediate/rapid gen-
otype status. No misclassification occurred in 
the group with slow genotype status and these 
individuals were not included in the model. 
Intermediate genotype status was associated 
with lower AFMU/1X and was therefore in-
cluded in the model as risk factor for misclas-
sification (OR=5.87, 95 %CI: 1.71-20.09, 
P=0.0049). Emptying the bladder before bev-
erage consumption was the only other factor 
reducing the odds ratio of misclassification 
significantly (OR=5.17, 95 %CI: 1.60-16.74, 
P=0.0061). 
The metabolite 1X was negatively associ-
ated with misclassification (r=-0.23, P=0.011, 
based on log-values), indicating that lower 
values of 1X more often lead to misclassifica-
tions, even though 1X factors in as denomina-
tor. As some measurements of the reference 
metabolite 1X were rather low, values of 1X 
might also be an indicator of how well the caf-
feine test in a participant went. In participants 
with 1X above the median of 98.25, there was 
no association with misclassification (r=0.01, 
P=0.96).    
 
TB history related to NAT2 phenotype and 
genotype status  
Sixteen of the 260 participants had a his-
tory of active TB before participating in the 
study, all received standard treatment, includ-
ing 300 mg isoniazid per day over six months 
according to WHO recommendations. All but 
one case came from Tasiilaq, East Greenland, 
a region with a particularly high TB incidence 
(Bjorn-Mortensen et al., 2015). Genotype sta-
tus was distributed as two slow, four interme-
diate and ten rapid. Reviewing their medical 
records revealed no cases of liver injury or 
treatment failure, i.e. all 13 cases with a posi-
tive culture test (three not tested) proved to be 
sensitive to standard treatment. 
 
DISCUSSION 
This study aimed to determine NAT2 phe-
notype status and to compare it to NAT2 gen-
otype status in 260 study participants from 
three towns in Greenland. Sequencing of the 
coding region of NAT2 detected no additional 
variation, so that the previously analyzed six 
polymorphic SNPs of the 7-SNP-panel were 
sufficient to assess NAT2 genotype status. 
NAT2 phenotype status was studied by the 
caffeine test and determined by the ratio of the 
metabolites AFMU and 1X. However, the 
concordance between genotype and pheno-
type status was rather poor and splitting the 
cohort in three groups showed that it was 
mainly the group with pH<3 where 
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AFMU/1X was low for individuals with inter-
mediate/rapid genotype status. In the context 
of this field study, the recommended manual 
adjustment to pH 3.5 was not feasible and we 
worked with a standard concentration of so-
dium hydrogen sulfate monohydrate. Here, 
the metabolite measurements appear rela-
tively stable in the pH range from 3 to 6, so 
that a strategy filling the sampled urine of a 
participant in two plastic tubes with two dif-
ferent concentrations of sodium hydrogen sul-
fate monohydrate might guarantee a urine 
sample with pH between 3 and 5 for each par-
ticipant in future studies. 
Analyses based on the urine metabolites 
were restricted to samples with pH>3, leaving 
143 participants. Here, 13 % showed a slow 
phenotype status despite intermediate/rapid 
genotype status. The observed correlation be-
tween NAT2 phenotype and genotype status 
is slightly lower than what has been reported 
in most other studies among different ethnic 
groups (Bolt et al., 2005; Butcher, 2002; 
Cascorbi et al., 1995; Parkin et al., 1997; Tang 
et al., 1991; Zhao et al., 2000). However, sub-
stantial discrepancies have also been reported. 
A study comparing the NAT2 phenotype and 
genotype status between Swedes and Koreans 
showed a significantly different enzyme ac-
tivity between the two groups, even when 
comparing the same NAT2 haplotypes 
(Djordjevic et al., 2012). Another study re-
ported both slow and rapid phenotypes among 
individuals with intermediate genotype status 
(Bolt et al., 2005).  
Investigating the two metabolites 1X and 
AFMU showed increased urine levels when 
caffeine was administered via coffee instead 
of cola or tea. The choice of coffee explained 
about 32 % of the variance of both metabo-
lites. Future studies could consider adminis-
tering 100 mg caffeine tablets to ensure a suf-
ficient caffeine intake. The genotype had a 
stronger effect on AFMU than on 1X. In-
creased levels of the metabolites were also 
observed for participants who smoked, were 
older, had higher creatinine levels, or were on 
a healthier diet according to the DQS. The un-
expected association between age and the me-
tabolite levels might not be caused directly by 
age, it is well possible that in the Greenlandic 
study group some relevant factors were corre-
lated with age but not measured. Further stud-
ies are needed to follow-up on this. Ultra-slow 
haplotypes (*6A and *7B) had a frequency of 
15 % in this study, and the number of ultra-
slow haplotypes significantly reduced 
AFMU/1X in regression models already ac-
counting for slow and intermediate genotype 
status. In our study, NAT2 genotypes explain 
72 % in the variability of AFMU/1X, which 
is not too far from the reported 88 % ex-
plained in isoniazid clearance (Kinzig-
Schippers et al., 2005). 
Misclassification was significantly more 
frequent in cases where the bladder was not 
emptied before drinking the beverage 
(OR=5.17, 95 %CI: 1.60-16.74). Together 
with the observation that the levels of the in-
dividual metabolites depend on several fac-
tors, it seems reasonable that deviations from 
a perfect trial set-up explain the remaining 
misclassifications.  
In conclusion, our study showed that in 
Greenland NAT2 genotype status can be de-
termined via six SNPs from the 7-SNP-panel. 
The concordance between the NAT2 pheno-
type and genotype status was corrupted in 
urine samples with a pH<3 and levels of the 
metabolites AFMU and 1X were lower when 
participants drank cola or tea instead of cof-
fee. Therefore, future field studies should en-
sure sufficient caffeine intake and carefully 
monitor the pH values of the urine samples. 
The considerable variation in AFMU/1X ob-
served in individuals with intermediate and 
rapid genotype status precludes increased iso-
niazid dose-regimes for these individuals be-
fore differences in enzyme activity are better 
understood. In contrast, all individuals with 
slow genotype status had slow enzyme activ-
ity and may very well benefit from a reduced 
isoniazid dose regime resulting in fewer ad-
verse events and possibly better compliance. 
Thus, our findings justify decreased isoniazid 
doses for TB patients with slow genotype sta-
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tus when at the same time treatment effective-
ness is carefully monitored. Future studies on 
plasma levels of acetyl-isoniazid in Green-
landic individuals with rapid genotype status 
are needed to justify increased doses of isoni-
azid for them. 
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